Related Experiment Video
Updated: Oct 18, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Mohamad Adham Salkeni1, Wajeeha Rizvi2, Kyaw Hein3
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
Even though gene amplification or protein overexpression occurs in approximately one-fifth of all breast cancers, the discovery of HER2 has, nevertheless, had profound implications for the disease. Indeed, the characterization of the receptor resulted in a number of significant advances. Structurally, unique features provided avenues for the development of numerous compounds with target-specificity; molecularly, biological constructs revealed a highly complex, internal signal transduction pathway with regulatory effects on tumor proliferation, survival, and perhaps, even resistance; and clinically, disease outcomes manifested its predictive and prognostic value. Yet despite the receptor's utility, the beneficial effects are diminished by tumor recurrence after neo- or adjuvant therapy as well as losses resulting from the inability to cure patients with metastatic disease. What these observations suggest is that while tumor response may be partially linked to uncoupling cell surface message reception and nuclear gene expression, as well as recruitment of the innate immune system, disease progression and/or resistance may involve a reprogrammable signaling mainframe that elicits alternative growth and survival signals. This review attempts to meld current perceptions related to HER2-positive metastatic breast cancer with particular attention to current biological insights and therapeutic challenges.
Insights
The discovery of Human Epidermal growth factor Receptor 2 (HER2) has advanced breast cancer treatment, but recurrence and metastatic disease persist. Understanding HER2 signaling is key to overcoming treatment resistance in HER2-positive breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Human Epidermal growth factor Receptor 2 (HER2) overexpression occurs in about 20% of breast cancers.
- HER2 characterization led to targeted therapies and improved understanding of cancer signaling pathways.
- Despite advances, challenges remain in treating recurrent and metastatic HER2-positive breast cancer.
Purpose of the Study:
- To review current understanding of HER2-positive metastatic breast cancer.
- To highlight biological insights and therapeutic challenges.
- To explore mechanisms of treatment resistance and disease progression.
Main Methods:
- Literature review of current research on HER2-positive breast cancer.
- Analysis of structural, molecular, and clinical implications of HER2.
- Synthesis of data on signaling pathways, immune system involvement, and therapeutic resistance.
Main Results:
- HER2's structural and molecular features enable targeted therapies.
- HER2 signaling pathways regulate tumor proliferation, survival, and resistance.
- Clinical utility of HER2 is limited by tumor recurrence and metastatic disease.
- Disease progression and resistance may involve reprogrammable signaling pathways.
Conclusions:
- While HER2 is crucial, therapeutic benefits are limited by resistance and metastasis.
- Understanding alternative signaling pathways is vital for improving treatment outcomes.
- Further research into HER2 biology and resistance mechanisms is needed for effective metastatic breast cancer treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...